Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 3, 2008, Pages 289-293

  Weiss, J J ^a   Bhatti, L ^b   Dieterich, D T ^a   Edli, N ^c   Fishbein, D A ^d   Goetz, M B ^e   Yu, K ^f   Wagner, G J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AIDS HEALTHCARE FOUNDATION   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e West la Kaiser Permanente ^*  (United States)

^f RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DEMOGRAPHY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; STATISTICAL ANALYSIS; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 58749112970     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03718.x     Document Type: Article

References (20)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
2. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
3. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12.
4. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
5. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005; 40(Suppl. 5): S349-54.
6. Rauch A, Egger M, Reichen J, Furrer H. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferonlpha plus ribavirin. J Acquir Immune Defic Syndr 2005; 38: 238-40.
7. Carrat F, Bani-Sadr F, Pol S, etal. Pegy-lated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
8. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
9. Torriani FJ, Rodriguez-Torres M, Rock- stroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
10. Fried MW, Shiffman ML, Reddy KR, etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
11. Sherman KE, Peters M, Koziel MJ. HIV and liver disease forum: conference proceedings. Hepatology 2007; 45: 1566-77.
12. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Aids 2007; 21: 1073-89.
13. Fumaz CR, Munoz-Moreno JA, Ballesteros AL, et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007; 19: 138-45.
14. Smith SR, Wahed AS, Kelley SS, Conje-evaram HS, Robuck PR, Fried MW. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007; 41: 1116-23.
15. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretro- viral medications. J Acquir Immune Defic Syndr 2002; 31(Suppl. 3): S103-6.
16. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS 2002; 16: 599-608.
17. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 968-77.
18. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 435-42.
19. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002; 17:1-11.
20. Weiss JJ, Bangsberg D. Psychiatric aspects of adherence to medical care and treatment. In: Cohen M, Gorman J, eds. Comprehensive Textbook of AIDS Psychiatry. New York: Oxford University Press, 2008: 281-95.